XML 73 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
May 09, 2022
May 03, 2022
Jul. 19, 2022
Apr. 26, 2022
Jul. 31, 2021
Dec. 31, 2022
Shareholders' Equity (Details) [Line Items]            
Aggregate offering price (in Dollars)         $ 45,000  
Sale of ordinary shares           1,065,057
Total amount (in Dollars)           $ 4,423
Net of issuance cost (in Dollars)           $ 222
Share option plan description   On May 3, 2022, the annual and extraordinary general meeting of shareholders of the Company approved a new grant of 76,120 options to the then current Chief Executive Officer of the Company, Mr. Amir Weisberg. In addition, it was approved to accelerate the vesting of 12,906 options from an outstanding grant; in both cases the vesting of all options will occur on June 30, 2022. As a result, the Company recognized a total share-based compensation expense in the amount of $76.         
Number of options 1,000,000          
Weighted average grant date fair value of options granted (in Dollars per share)           $ 3.46
Expected dividend yield           0.00%
Unrecognized compensation costs (in Dollars)           $ 6,379
Recognized over weighted average period           2 years 6 months
Warrants, description           During the year ended December 31, 2021, 580,028 D-2 warrants were exercised into 115,982 Ordinary shares on a cashless basis. In addition, 68,491 D-2 warrants were exercised into 68,491 Ordinary shares for a total consideration of $632. As of December 31, 2022, no D-2 warrants are outstanding.
Warrants outstanding          
Warrant to purchase ordinary shares (in Dollars)     $ 120 $ 468    
Warrant [Member]            
Shareholders' Equity (Details) [Line Items]            
Warrants, description           During the year ended December 31, 2020, 2,106,879 D-2 warrants were exercised into 885,377 Ordinary shares on a cashless basis. As of December 31, 2020, 648,519 D-2 warrants were outstanding. In addition, 53,775 A warrants were exercised into 53,775 Ordinary shares for a total consideration of $13.
2012 Share Option Plan [Member]            
Shareholders' Equity (Details) [Line Items]            
Stock option vesting period           The options granted generally have a four-year vesting period and expire ten years after the date of grant.
Stock options available for future grants           700,965
Minimum [Member]            
Shareholders' Equity (Details) [Line Items]            
Stock option shares 3,672,094          
Maximum [Member]            
Shareholders' Equity (Details) [Line Items]            
Stock option shares 4,672,094          
Officers [Member] | 2012 Share Option Plan [Member]            
Shareholders' Equity (Details) [Line Items]            
Share option plan grant           4,672,094